Pharmalys Strengthens Clinical Research Capacity in West Africa: Insights from the CECaBI II Workshop in Abidjan

May 7, 2025 | Capacity building

As part of an ongoing commitment to strengthening clinical research standards across Africa, Pharmalys participated in the CECaBI II workshop, held on April 24 -25, 2025, in Abidjan, Côte d’Ivoire. The event was a key milestone in clinical research capacity building in West Africa, bringing together stakeholders from various sectors to exchange knowledge on clinical trials, Good Clinical Practice (GCP), and research ethics.

Dr. Karim Bagaté, Pharmalys’ Director of Clinical Operations and Safety, chaired the stakeholders consultation meeting in collaboration with the Institut Pasteur de Paris. His participation in the workshop was an important part of the discussions on strengthening Côte d’Ivoire’s clinical research infrastructure and ‘opening up job opportunities for young graduates in medicine, pharmacy, and science’.

 

The CECaBI II project involves collaboration between key institutions such as the National Ethics Committee of Life and Health Sciences (CNESVS), the Ivorian Pharmaceutical Regulatory Authority (AIRP), EthixPERT, Institut Pasteur de Paris, and the National Health Research Ethics Committee of Senegal. The collaboration between these organisations is key to ensuring that Côte d’Ivoire has a solid foundation for conducting clinical trials that are ethical, transparent, and scientifically rigorous.

Through the CECaBI II project, the focus is placed on improving training for professionals and enhancing the regulatory environment to support high-quality research practices. The outcome of the project is expected to be a meaningful step forward in addressing the healthcare challenges in Côte d’Ivoire and in building a more sustainable clinical research landscape across West Africa.

For more information about Pharmalys’ commitment to capacity building in clinical research, click here.

A Breakthrough in Malaria Care for the Youngest Patients

A Breakthrough in Malaria Care for the Youngest Patients

It’s a sobering truth: malaria still claims the lives of hundreds of thousands of children every year, with the youngest being most at risk. Until now, doctors treating newborns and very small infants under 5 kg faced a dilemma - no treatment had ever been designed...

The Microbiome and Cancer: What Do We Know?

The Microbiome and Cancer: What Do We Know?

Insights from research and an interview with Dr Jennifer Wargo, MD, University of Texas M.D. Anderson Cancer Center, as featured in a recent JAMA interview. The human body is home to trillions of microbes - bacteria, viruses, fungi, and other microorganisms - that...

A spotlight on the Pharmalys Regulatory Affairs Unit

A spotlight on the Pharmalys Regulatory Affairs Unit

As clinical research expands rapidly across the African continent, the demand for strategic and locally grounded regulatory support is becoming more critical than ever. From clinical trial start-up to post-marketing activities, effective regulatory oversight is key to...

Pharmalys at the EDCTP Forum, Kigali 2025

Pharmalys at the EDCTP Forum, Kigali 2025

Pharmalys participated as an exhibitor at the EDCTP Forum 2025, held from 15 to 20 June 2025 in Kigali, Rwanda. The event brought together a diverse community of stakeholders, providing a unique platform for collaboration, learning, and visibility. This year’s theme,...

Highlights from the Pharmalys Voice meeting, June 2025

Highlights from the Pharmalys Voice meeting, June 2025

On June 26, 2025, Pharmalys held its second Pharmalys Voice meeting of the year, bringing together colleagues from across the company in a dynamic and interactive virtual gathering. The meeting was marked by thoughtful presentations, engaging discussions, and a sense...